% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Gao:166141,
      author       = {X. Gao$^*$ and Y. Zhang$^*$ and D. Boakye$^*$ and X. Li$^*$
                      and J. Chang-Claude$^*$ and M. Hoffmeister$^*$ and H.
                      Brenner$^*$},
      title        = {{W}hole blood {DNA} methylation aging markers predict
                      colorectal cancer survival: a prospective cohort study.},
      journal      = {Clinical epigenetics},
      volume       = {12},
      number       = {1},
      issn         = {1868-7083},
      address      = {[S.l.]},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2020-02649},
      pages        = {184},
      year         = {2020},
      abstract     = {Blood DNA methylation-based aging algorithms predict
                      mortality in the general population. We investigated the
                      prognostic value of five established DNA methylation aging
                      algorithms for patients with colorectal cancer
                      (CRC).AgeAccelHorvath, AgeAccelHannum, DNAmMRscore,
                      AgeAccelPheno and AgeAccelGrim were constructed using whole
                      blood epi-genomic data from 2206 CRC patients. After a
                      median follow-up of 6.2 years, 1079 deaths were documented,
                      including 596 from CRC. Associations of the aging algorithms
                      with survival outcomes were evaluated using the Cox
                      regression and survival curves. Harrell's C-statistics were
                      computed to investigate predictive performance.Adjusted
                      hazard ratios $(95\%$ confidence intervals) of all-cause
                      mortality for patients in the third compared to the first
                      tertile were 1.66 (1.32, 2.09) for the DNAmMRscore, 1.35
                      (1.14, 1.59) for AgeAccelPheno and 1.65 (1.37, 2.00) for
                      AgeAccelGrim, even after adjustment for age, sex and stage.
                      AgeAccelHorvath and AgeAccelHannum were not associated with
                      all-cause or CRC-specific mortality. In stage-specific
                      analyses, associations were much stronger for patients with
                      early or intermediate stage cancers (stages I, II and III)
                      than for patients with metastatic (stage IV) cancers.
                      Associations were weaker and less often statistically
                      significant for CRC-specific mortality. Adding DNAmMRscore,
                      AgeAccelPheno or AgeAccelGrim to models including age, sex
                      and tumor stage improved predictive performance
                      moderately.DNAmMRscore, AgeAccelPheno and AgeAccelGrim could
                      serve as non-invasive CRC prognostic biomarkers independent
                      of other commonly used markers. Further research should aim
                      for tailoring and refining such algorithms for CRC patients
                      and to explore their value for enhanced prediction of
                      treatment success and treatment decisions.},
      cin          = {C070 / HD01 / C020 / C120},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)C020-20160331 / I:(DE-He78)C120-20160331},
      pnm          = {313 - Cancer risk factors and prevention (POF3-313)},
      pid          = {G:(DE-HGF)POF3-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:33256852},
      doi          = {10.1186/s13148-020-00977-4},
      url          = {https://inrepo02.dkfz.de/record/166141},
}